ReviewThe Journal of antibiotics2025
Biosynthesis of antibiotics with sulfonamide and azaindane moieties.
Review in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging enzymatic strategies for the synthesis of α-tertiary amino acids.Communications chemistry · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
As research into the biosynthesis of natural products has matured, the biosynthetic pathways of common skeletons have been identified one after another, and attention is now being focused on research into the biosynthetic machineries of compounds with rare skeletons. Such research has the potential for leading to the discovery of new biosynthetic enzymes and artificial biosynthesis of unnatural compounds. In this study, I introduce the biosynthetic research on altemicidin, SB-203207, and SB-203208, which are rare natural products containing sulfonamide and azaindane skeletons. Further, self-resistance gene mining, the biosynthetic machineries of aminoacyl transferases, the synthesis of sulfonamides and azaindanes, and the structural basis and reaction mechanism of the biosynthetic enzyme SzbP, which uses beta-nicotinamide adenine dinucleotide (β-NAD) and S-adenosylmethionine (SAM) as substrates to create the first intermediate in the biosynthesis, are discussed in detail.
Indexed as
Identifiers
40195472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.